LakePharma ups biologics offering with Massachusetts site

By Flora Southey

- Last updated on GMT


Related tags Biotechnology

CDMO LakePharma has acquired a former-Stryker facility in Massachusetts to boost clinical biomanufacturing services.

The US-based contract development and manufacturing organisation (CDMO) moved into the 69,000 sq. ft. site – located at 35 South Street, Hopkinton – last week, which includes laboratory, office space, and dedicated manufacturing space.

LakePharma said the site offers clients “microbiomanufacturing”​ services, which spokesperson Brendan Doherty told us refers to single use, small scale bioprocessing.

And according to the CDMO, the facility will be used to “develop the site to perform GMP [good manufacturing practice] biologics manufacturing for Phase I clinical trials.”

“The increased capacity at the site will also support growth in LakePharma’s assay development, bioanalytical, process development and QC [quality control] services,” ​it added.

LakePharma plans to add approximately 100 positions at the site by 2020.

New customers?

Doherty told us offering more “integrated services” ​will be attractive to existing and potential new customers.

CEO Hua Tu said the site location will also an advantage.

“Hopkinton is in close proximity to Cambridge/Boston, where we have a large cluster of clients, and we believe that this facility will increase our ability to serve their product development and manufacturing needs.”

The CDMO has a vector facility in Worcester, MA – where it plans to double its molecular biology and cell culture operations later this year – a development centre in Hayward, CA, and antibody-focused centres in South San Francisco and Belmont, CA.

South Road site

Doherty told us South Road facility is a former Stryker site.

Olympus Biotech purchased​ Stryker Biotech in 2010.

In February, 2014 Olympus Corporation announced plans​ to discontinue its US biotechnology division, Olympus Biotech, including the closure of its Hopkinton, MA facility.

Related news

Show more

Related products

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more